The Intent of the Haim Pharma Group Quality Policy is to define the Quality Vision for all activities undertaken by the Haim Pharma Group.

Policy

The Quality Policy is delivered through our Quality Objectives encompassing safety, quality, and legislative compliance of Haim Pharma Group products to meet customer, consumer, and regulatory requirements. It is founded on the belief that through continuous monitoring we can learn and improve to avoid serious quality and service issues, increase speed to market, and reduces the cost of error.
The Haim Pharma Group Quality Policy is linked to the core value of responsible leadership, effectiveness, and efficiency while ensuring all Haim Pharma Group employees, service providers, and suppliers and treated with kindness and respect.

Scope

Quality is to be applied by every employee to every aspect of our activities daily to ensure

  • Safety
  • Quality
  • Regulatory Compliance
  • Sustainability

This policy and associated procedures apply to all directors, staff, and contractors working for the company.

Policy

The Quality Policy is executed under the guidance of the Quality Management System (QMS) and its associated policies and procedures, in conjunction with the Haim Pharma Risk Management Plan.

Legislative Requirements

Haim Pharma Group Ltd. Policies and Procedures are written to comply with or to provide guidance to the standards listed below.

  • Eudralex Volumes 1-10 EU Legislation & Guidelines for Medicinal products
  • European Union Good Manufacturing Practices (EU GMP)
  • The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Standards
  • United States Food and Drug Administration (FDA) 21 Code of Federal Regulations (CFR) Parts 11, 210 & 211
  • World Health Organisation (WHO) GMPs for Pharmaceutical products
  • European Union Good Manufacturing Practices (EU GMP)
  • Good Manufacturing Practices (cGMP),
  • Good Distribution Practice (GDP)

END OF POLICY